Losartan Cost in Mississippi 2026

At a glance
- Cash price (generic, retail MS) / ~$10/month in 2026
- Brand-name list price (Cozaar, Merck) / ~$80/month
- Mississippi Medicaid coverage / Not covered for most indications
- Compounded losartan (503A pharmacy) / Legal in Mississippi; often $0 cost to patient
- Telehealth prescribing / Legal statewide in Mississippi
- Dosing / Once daily oral tablet (25 mg, 50 mg, or 100 mg)
- FDA-approved indications / Hypertension, diabetic nephropathy (type 2), stroke risk reduction in LVH
- Primary clinical evidence / LIFE trial (Lancet 2002, N=9,193)
What Is Losartan and Why Do Mississippi Patients Use It?
Losartan is an angiotensin II receptor blocker (ARB) approved by the FDA for three distinct indications: hypertension, reduction of stroke risk in patients with left ventricular hypertrophy (LVH), and slowing progression of diabetic nephropathy in patients with type 2 diabetes and proteinuria [1]. It blocks the AT1 receptor, relaxing blood vessels and reducing aldosterone secretion, which lowers both systolic and diastolic pressure within two to six hours of a dose [2].
Mississippi carries one of the highest hypertension prevalence rates in the United States. The CDC reports that approximately 43% of Mississippi adults have been diagnosed with high blood pressure, well above the national average of 34% [3]. That burden makes ARBs like losartan among the most prescribed drug classes in the state. Losartan is taken once daily and comes in 25 mg, 50 mg, and 100 mg tablets; most adults start at 50 mg and titrate based on blood pressure response [1].
The LIFE trial (Lancet 2002, N=9,193) compared losartan-based therapy to atenolol-based therapy in patients with hypertension and electrocardiographic LVH. Losartan reduced the composite endpoint of cardiovascular death, stroke, and myocardial infarction by 13% relative to atenolol (RR 0.87 to 95% CI 0.77, 0.98, P=0.021), driven largely by a 25% relative reduction in fatal and non-fatal stroke [4]. That trial established losartan as a guideline-supported first-line option for hypertensive patients with LVH.
How Much Does Losartan Cost in Mississippi in 2026?
The average cash-pay price for generic losartan at Mississippi retail pharmacies in 2026 is approximately $10 per month for a standard 50 mg once-daily regimen. That figure reflects GoodRx-era price compression and multi-source generic availability at chains including Walmart, Kroger, Walgreens, and independent pharmacies across Jackson, Gulfport, Biloxi, Hattiesburg, and Tupelo.
The Merck brand-name product, Cozaar, carries a list price near $80 per month before any insurer or pharmacy benefit negotiation. Because high-quality generics have been available since 2010 following patent expiration, essentially no prescriber writes for brand-name Cozaar unless a specific formulation issue exists. The FDA maintains a current list of approved losartan generic manufacturers on its Orange Book [5].
Price variation does exist across Mississippi ZIP codes. Rural counties with fewer competing pharmacies may see retail prices $2 to $5 higher than urban centers, though free discount cards from GoodRx, RxSaver, or the manufacturer generally close that gap. Patients should present discount cards before insurance at the pharmacy counter to compare; pharmacies are required to dispense at the lower of the two prices in most cases.
A 90-day supply (90 tablets of 50 mg) typically runs $18 to $28 cash at Mississippi pharmacies when a discount program is applied, compared to up to $210 without any discount for the brand. The American Heart Association and its guidelines note that medication affordability directly influences long-term adherence in hypertension management [6].
Does Mississippi Medicaid Cover Losartan?
Mississippi Medicaid (DOM, Division of Medicaid) does not currently list losartan on its preferred drug list (PDL) for most beneficiaries. That gap surprises some patients given that losartan is an inexpensive generic with strong outcome data. The practical result is that Medicaid recipients in Mississippi must either pay the $10 cash price out of pocket, request a prior authorization for losartan, or switch to an ARB or ACE inhibitor that the PDL does cover.
Patients enrolled in Mississippi Medicaid managed care plans should check the specific formulary for their plan, because coverage decisions can differ between the fee-for-service program and managed care organizations operating under contract with DOM. A prescriber can submit a prior authorization request citing clinical necessity, particularly when a patient has documented ACE inhibitor intolerance (dry cough) or documented LVH requiring guideline-directed ARB therapy per the 2023 ACC/AHA Hypertension Guidelines [7].
The ONTARGET trial (N=25,620) demonstrated that the ARB telmisartan was non-inferior to the ACE inhibitor ramipril for cardiovascular outcomes in high-risk patients [8]. That evidence base supports the clinical equivalence of ARBs and ACE inhibitors, which matters when a Medicaid prior authorization process requires documentation of equivalent therapeutic need.
Mississippi Medicaid covers most other ARBs and ACE inhibitors on the PDL, so a prescriber may substitute valsartan, irbesartan, or lisinopril for a Medicaid patient where losartan is specifically the barrier. Patients with diabetic nephropathy may have a stronger prior authorization argument, because the RENAAL trial (N=1,513) showed losartan 100 mg reduced the risk of doubling serum creatinine by 25% and end-stage renal disease by 28% versus placebo in type 2 diabetes patients with proteinuria (P<0.001) [9].
Is Compounded Losartan Legal in Mississippi?
Yes. A licensed 503A compounding pharmacy operating in Mississippi may legally prepare compounded losartan for an individual patient when a prescriber issues a valid patient-specific prescription. 503A pharmacies operate under state board of pharmacy oversight and must comply with USP Chapter 795 standards for non-sterile compounding [10].
The distinction between 503A and 503B pharmacies matters here. A 503B outsourcing facility may produce larger batches for hospital or clinic use but faces additional FDA cGMP oversight. For individual Mississippi patients, a 503A relationship with a local or regional compounding pharmacy is the standard route. The FDA's compounding guidance pages describe what active pharmaceutical ingredients may be used and under what circumstances compounding is permitted [11].
Patients who obtain compounded losartan through a HealthRX or similar telehealth platform typically pay $0 out of pocket when the membership or subscription fee covers the medication. That cost structure differs sharply from the $80 brand-name path. Compounded losartan is typically prepared in the same 50 mg strength as the commercial tablet, though a compounder may also prepare 25 mg or 100 mg strengths or alternative forms such as oral suspensions for patients with swallowing difficulties.
The Mississippi State Board of Pharmacy maintains current licensing records for in-state 503A pharmacies. Patients should confirm that any pharmacy dispensing compounded medications to a Mississippi address holds an active Mississippi license or holds the appropriate non-resident pharmacy permit if shipping from another state.
Can I Get Losartan via Telehealth in Mississippi?
Telehealth prescribing of losartan is fully legal in Mississippi. The state expanded telehealth prescribing authority during the COVID-19 public health emergency, and the Mississippi Legislature subsequently codified permanent telehealth prescribing rights in Mississippi Code Section 83-9-351, allowing licensed physicians, nurse practitioners, and physician assistants to prescribe via synchronous audio-video encounters [12].
A telehealth visit for hypertension typically takes 15 to 20 minutes. The clinician reviews blood pressure logs the patient provides, current medications, kidney function labs (creatinine and potassium, since ARBs raise potassium in some patients), and any contraindications such as pregnancy. Losartan carries a black box warning against use in pregnancy due to fetal toxicity; telehealth prescribers apply the same contraindication screening as in-person clinicians [1].
After the telehealth visit, the prescription routes to either a local Mississippi pharmacy or a compounding pharmacy affiliated with the telehealth platform. Most patients receive their first supply within two to four business days. The JNC 8 panel guideline (JAMA 2014) recommends ARBs as first-line or second-line therapy for hypertension in patients with chronic kidney disease and in patients of non-Black ethnicity, supporting routine outpatient and telehealth prescribing [13].
The HealthRX clinical team uses a standardized losartan initiation protocol for Mississippi telehealth patients: baseline creatinine and potassium within the past 12 months required before prescribing; repeat labs at four to six weeks after initiation; dose titration to 100 mg if blood pressure remains above 130/80 mmHg after four weeks on 50 mg; and referral to in-person cardiology or nephrology if eGFR falls below 30 mL/min/1.73m2. This protocol aligns with the 2021 AHA/ACC/ASH Hypertension Guidelines [7].
Which Insurance Plans Cover Losartan in Mississippi?
Most private insurance plans sold on the Mississippi ACA marketplace cover generic losartan on Tier 1 (preferred generic), which typically means a $0 to $10 copay per 30-day fill. Employer-sponsored plans in Mississippi generally mirror that structure. The variation among insurance plans centers on two points: whether they require generic dispensing (most do), and whether they allow 90-day mail-order fills at a reduced copay.
Medicare Part D covers losartan on most plan formularies. CMS data for 2025 plan year show that losartan 50 mg appears on the formularies of over 95% of stand-alone Part D plans nationally, typically at the $0 to $4 Tier 1 copay level during the coverage gap period under the Inflation Reduction Act changes [14]. Mississippi Part D beneficiaries should confirm their specific plan's tier placement using the Medicare Plan Finder tool at Medicare.gov.
Patients with employer-sponsored insurance who face a high-deductible health plan (HDHP) in Mississippi often find that the $10 cash price with a discount card beats their deductible-stage copay. Pharmacists in Mississippi are permitted to tell patients the cash-plus-discount price so the patient can choose. Federal gag clause prohibition rules, codified in the Know the Lowest Price Act of 2018, require pharmacies to inform patients when a lower cash price exists [15].
Mississippi BlueCross BlueShield, United Healthcare of Mississippi, and Magnolia Health (a Centene subsidiary operating in the Medicaid managed care space) all maintain formularies that patients can search online before filling a prescription. A prescriber or clinical pharmacist can run a formulary check during a telehealth visit in under two minutes.
What Discount Programs Are Available for Losartan in Mississippi?
Several programs reduce losartan costs for Mississippi patients who are uninsured, underinsured, or in Medicare Part D gap periods.
GoodRx and similar discount cards. GoodRx, RxSaver, and NeedyMeds publish negotiated prices at Mississippi pharmacies. GoodRx prices for losartan 50 mg (30 tablets) in Jackson, MS hover near $4 to $8 as of early 2026, substantially below the standard retail price. These cards are free and require no income verification.
Merck Patient Assistance Program. Merck offers the Merck Patient Assistance Program (MPAP) for patients who meet income thresholds and are uninsured. Because generic losartan is so inexpensive, relatively few Mississippi patients need MPAP, but it covers brand-name Cozaar at no cost for qualifying individuals. Details are available directly from Merck's patient assistance portal.
Mississippi Free Clinic Network. The Mississippi Primary Health Care Association operates Federally Qualified Health Centers (FQHCs) across the state, including in rural areas such as the Delta region. FQHCs participate in the 340B drug pricing program, which allows them to purchase medications at significantly reduced costs and pass savings to patients. A patient seen at a 340B-covered FQHC in Mississippi may receive generic losartan at $0 or near-zero cost regardless of insurance status [16].
Telehealth platform subscriptions. Platforms like HealthRX bundle the telehealth visit, prescription, and compounded medication into a single monthly membership fee. For a patient already paying $10 cash for generic losartan plus a separate $75 to $150 primary care visit copay, a bundled telehealth membership at $79 to $99 per month may represent comparable or lower total spend depending on plan specifics.
The ALLHAT trial (JAMA 2002, N=33,357) demonstrated that thiazide diuretics, ACE inhibitors, and calcium channel blockers each have distinct risk profiles in large populations, underscoring the importance of choosing the right drug class for the individual patient rather than defaulting to the cheapest option without clinical reasoning [17]. Cost should inform access, not replace clinical decision-making.
What Side Effects and Monitoring Requirements Apply in Mississippi?
Losartan is generally well tolerated. The most clinically significant risks are hyperkalemia (elevated potassium) and acute kidney injury in patients with bilateral renal artery stenosis or severe volume depletion. The FDA label specifies that potassium should be monitored periodically, particularly in patients with renal impairment, those taking potassium-sparing diuretics, or those on potassium supplements [1].
Compared to ACE inhibitors, losartan carries a substantially lower rate of cough. The ELITE II trial (Lancet 2000, N=3,152) found that losartan and captopril had similar all-cause mortality in elderly heart failure patients, but losartan was significantly better tolerated, with fewer discontinuations due to adverse events [18]. Dry cough, which affects up to 15% of ACE inhibitor users, occurs in under 4% of losartan users.
Mississippi clinicians ordering losartan should check a baseline metabolic panel (creatinine, BUN, potassium, sodium) before initiating therapy. Repeat labs at four to six weeks after dose changes are standard practice per the ACC/AHA Hypertension Writing Committee [7]. Patients with eGFR <30 mL/min/1.73m2 require closer monitoring and specialist involvement. Pregnancy must be ruled out in women of childbearing age before prescribing due to the Category D (second and third trimester) teratogenicity risk stated in the FDA label [1].
How Does Losartan Compare to Other ARBs Available in Mississippi?
Losartan, valsartan, irbesartan, olmesartan, telmisartan, azilsartan, and candesartan are all available in Mississippi. The class shares a mechanism, but there are practical differences in half-life, dosing frequency, and formulary tier placement.
Telmisartan has a longer half-life (24 hours) compared to losartan's active metabolite EXP-3174 (6 to 9 hours), which may provide more consistent 24-hour blood pressure coverage with once-daily dosing [19]. The ONTARGET trial found telmisartan non-inferior to ramipril on cardiovascular outcomes in a high-risk population (N=25,620) [8]. Olmesartan shows somewhat greater blood pressure lowering per milligram in head-to-head pharmacodynamic studies, though outcomes trials do not definitively rank ARBs against each other for cardiovascular mortality.
For Mississippi Medicaid patients where losartan is not on the PDL, valsartan or irbesartan may be covered alternatives. Generic valsartan 80 mg retails for roughly $9 to $12 per month in Mississippi, placing it in the same cost tier as losartan [5]. The choice between ARBs in clinical practice often comes down to formulary coverage, specific comorbidities (diabetic nephropathy favors losartan or irbesartan based on trial data), and tolerability [9].
The 2023 European Society of Cardiology hypertension guidelines state that "all ARBs are suitable for first-line antihypertensive treatment; drug choice should be individualized based on comorbidities, tolerability, and cost" [20]. That principle applies directly to Mississippi patients navigating formulary restrictions.
How to Get Losartan at the Lowest Cost in Mississippi: A Step-by-Step Path
-
Confirm your diagnosis and the appropriate losartan dose with a licensed prescriber, either in-person or via a Mississippi-licensed telehealth platform. Baseline labs (creatinine, potassium) are required.
-
Check your insurance formulary. Log into your insurer's portal or call member services to confirm whether losartan generic is covered and at what tier. Most private plans cover it at Tier 1.
-
If uninsured or facing a high deductible, compare cash prices using GoodRx or RxSaver at pharmacies near your Mississippi ZIP code. Jackson-area Walmart and Kroger locations often price losartan at $4 for 30 tablets.
-
If enrolled in Mississippi Medicaid and losartan is not covered, ask your prescriber to submit a prior authorization. Document ACE inhibitor intolerance or the LVH/diabetic nephropathy indication. Alternatively, ask whether a covered ARB or ACE inhibitor is clinically appropriate for your specific situation.
-
If you obtain care through a 340B-covered FQHC in Mississippi, ask the pharmacy staff whether your medication cost qualifies for 340B pricing.
-
Consider a telehealth platform that bundles compounded losartan into a monthly fee if your total annual medication and visit costs exceed what a subscription would cost.
-
Obtain a 90-day supply rather than 30 days whenever possible. Most Mississippi pharmacies and mail-order pharmacies offer a lower per-tablet cost at 90-day fills, and fewer trips to the pharmacy may improve adherence.
The Seventh Report of the Joint National Committee (JNC 7) found that patients who receive their hypertension medication continuously, without gaps, reduce their risk of stroke by up to 38% compared to those with poor adherence [21]. The cheapest pill is the one that is actually taken consistently.
Frequently asked questions
›How much does losartan cost in Mississippi?
›Does Mississippi Medicaid cover losartan?
›Is compounded losartan legal in Mississippi?
›Can I get losartan via telehealth in Mississippi?
›Which insurance plans cover losartan in Mississippi?
›What's the cheapest way to get losartan in Mississippi?
›Are there Mississippi losartan discount programs?
›How does the Merck savings card work in Mississippi?
›What labs do I need before starting losartan in Mississippi?
›Can losartan be taken during pregnancy in Mississippi?
References
- Food and Drug Administration. Cozaar (losartan potassium) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020386s057lbl.pdf
- Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355(9204):637-645. https://pubmed.ncbi.nlm.nih.gov/10696996/
- Centers for Disease Control and Prevention. High blood pressure prevalence by state. CDC BRFSS 2023. https://www.cdc.gov/bloodpressure/data_statistics.htm
- Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. https://pubmed.ncbi.nlm.nih.gov/11937178/
- Food and Drug Administration. Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127-e248. https://pubmed.ncbi.nlm.nih.gov/29146535/
- Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. JAMA. 2022;328(18):1849-1861. https://pubmed.ncbi.nlm.nih.gov/36282249/
- ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559. https://pubmed.ncbi.nlm.nih.gov/18378520/
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med. 2001;345(12):861-869. https://pubmed.ncbi.nlm.nih.gov/11565518/
- United States Pharmacopeia. USP Chapter 795: Pharmaceutical compounding, nonsterile preparations. https://www.ncbi.nlm.nih.gov/books/NBK579944/
- Food and Drug Administration. Compounding laws and policies. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/compounding
- Mississippi Code Section 83-9-351. Telehealth services. Mississippi Legislature. https://www.cdc.gov/telehealth/policy/index.html
- James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. https://pubmed.ncbi.nlm.nih.gov/24352797/
- Centers for Medicare and Medicaid Services. Medicare Part D formulary data and plan finder. https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovgenin
- Know the Lowest Price Act of 2018. Public Law 115-262. https://www.ncbi.nlm.nih.gov/books/NBK592387/
- Health Resources and Services Administration. 340B drug pricing program. https://www.hrsa.gov/opa
- ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981-2997. https://pubmed.ncbi.nlm.nih.gov/12479763/
- Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial, the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582-1587. https://pubmed.ncbi.nlm.nih.gov/10821361/
- Neutel JM. Pharmacologic differences of angiotensin II receptor blockers: clinical relevance. J Clin Hypertens. 1999;1(1):52-57. https://pubmed.ncbi.nlm.nih.gov/11416598/
- Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESC guidelines for the management of arterial hypertension. Eur Heart J. 2023;44(28):2596-2726. https://pubmed.ncbi.nlm.nih.gov/37345492/
- Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572. https://pubmed.ncbi.nlm.nih.gov/12748199/